Mor F, Cohen I R
Department of Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Int Arch Allergy Immunol. 1995 Dec;108(4):345-9. doi: 10.1159/000237180.
The current therapy for human autoimmune disease is based on nonselective immunosuppression achieved by corticosteroids or cytotoxic drugs. This form of therapy is toxic and frequently not effective in curing the disease. The study of experimental autoimmune disease models indicates that the pathogenic population of immune cells is restricted in terms of T-cell receptor gene usage and peptide epitopes recognized in the self-antigens. The recent developments in understanding of the pathophysiology of autoimmune disease point to the crucial role of the pathogenic T cell, the autoantigenic peptide, and the major histocompatibility complex molecules as well as the regulatory T-cell population in the disease process. The purpose of this review is to describe the use of vaccines to prevent and treat autoimmune disease. Encouraging results in animal models using vaccines based on the pathogenic T cell or the autoantigen have prompted the design of novel and selective immune-based therapies for human autoimmune disease.
目前针对人类自身免疫性疾病的治疗方法是基于皮质类固醇或细胞毒性药物实现的非选择性免疫抑制。这种治疗方式具有毒性，且在治愈疾病方面常常无效。对实验性自身免疫性疾病模型的研究表明，免疫细胞的致病群体在T细胞受体基因使用情况以及在自身抗原中识别的肽表位方面受到限制。对自身免疫性疾病病理生理学认识的最新进展表明，致病T细胞、自身抗原肽、主要组织相容性复合体分子以及调节性T细胞群体在疾病过程中起着关键作用。本综述的目的是描述疫苗在预防和治疗自身免疫性疾病中的应用。在基于致病T细胞或自身抗原的动物模型中取得的令人鼓舞的结果促使人们设计针对人类自身免疫性疾病的新型且基于免疫的选择性疗法。
